Related Experiment Videos
Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma
C D Schiller1, M R Schneider, H Hartmann
1Institute of Pharmacy, University of Regensburg, FRG.
Abstract:
Adrenal androgens are discussed as a reason for tumor progression after androgen ablation therapy. Because of the difference in the secretion of androgens by the adrenals of humans and rats, there is no reliable tumor model to study the role of adrenal androgens in tumor progression. Therefore, the main adrenal androgens were administered to rats in order to mimic human endocrine conditions. Application of dehydroepiandrosteron-sulfate (DHEA-S) alone or a mixture of androstendione (A), 11 beta-hydroxyandrostendione (OHA), dehydroepiandrosterone (DHEA), and its sulfate (DHEA-S) to castrated rats caused only a slight increase of prostate and seminal vesicle weight. Contrary to these findings, growth of the R3327 prostatic carcinoma in castrated rats was greatly stimulated by these adrenal androgens up to the level of the intact control. Thus, in spite of androgen ablation, tumor progression could be induced by exogenous adrenal androgens.
Insights
Adrenal androgens can drive tumor progression even after androgen ablation therapy. This study used rats to mimic human conditions, showing exogenous adrenal androgens stimulated prostate cancer growth.
Area of Science:
- Endocrinology
- Oncology
- Urology
Background:
- Adrenal androgens contribute to tumor progression following androgen ablation therapy.
- A lack of reliable rat models hinders studying adrenal androgens' role due to species-specific secretion differences.
- Human endocrine conditions were mimicked in rats to investigate adrenal androgen effects.
Purpose of the Study:
- To investigate the role of exogenous adrenal androgens in promoting tumor progression after androgen ablation.
- To establish a more accurate preclinical model for studying prostate cancer under human-like endocrine conditions.
Main Methods:
- Administration of dehydroepiandrosterone-sulfate (DHEA-S) alone or a mixture of androstendione (A), 11 beta-hydroxyandrostendione (OHA), dehydroepiandrosterone (DHEA), and DHEA-S to castrated rats.
- Monitoring prostate and seminal vesicle weight changes.
- Assessing the growth of R3327 prostatic carcinoma in treated castrated rats.
Main Results:
- Slight increases in prostate and seminal vesicle weight were observed with DHEA-S or the androgen mixture.
- Significant stimulation of R3327 prostatic carcinoma growth was observed in castrated rats treated with exogenous adrenal androgens.
- Tumor growth reached levels comparable to intact control rats.
Conclusions:
- Exogenous administration of key adrenal androgens can induce prostate cancer progression in castrated rats.
- This study demonstrates that adrenal androgens can overcome androgen ablation therapy, highlighting their clinical significance.
- The findings suggest a potential therapeutic target for managing prostate cancer progression in patients undergoing androgen deprivation.